Ipamorelin vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | Tesamorelin |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 2 mg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
Ipamorelin, Tesamorelin are both commonly used for:
Key Differences
Unique to Ipamorelin:
Which Has Stronger Evidence?
- Muscle Growth: Ipamorelin has stronger research support.
| Goal | Ipamorelin | Tesamorelin |
|---|---|---|
| Muscle Growth | high | medium |
| Fat Loss | high | high |
Key Studies
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?